Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-01-29 Board/Management Inform…
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 24, 2024, reporting the appointment of a new Chief Financial Officer, Jason A. Amello. The content focuses on management changes, including details about the new CFO's background, employment agreement, and related arrangements. There is no financial data or report content, but rather an announcement of a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length (8478 characters) supports it being a full announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2024-01-29 English
4
Director's Dealing
2023-12-21 English
4
Director's Dealing
2023-12-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 9, 2023, by TScan Therapeutics, Inc. It reports initial results from a Phase 1 clinical trial and includes a press release and presentation materials as exhibits. The content focuses on clinical trial data and a virtual event announcement, not on financial results or detailed financial statements. The document is a current report disclosing material events or updates rather than a full financial report or earnings release. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is a regulatory filing reporting material events and disclosures as required by the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7515 characters) and content confirm it is not merely an announcement of a report but a current report filing with substantive disclosure, fitting the RNS category best.
2023-12-11 English
4
Director's Dealing
2023-12-08 English
3
Director's Dealing
2023-12-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.